Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

23andMe Holding Co. T.ME


Primary Symbol: ME

Consumer Cyclical Healthcare Advertising Agencies
23andMe Holding Co. is a genetics-led consumer healthcare and biopharmaceutical company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.


NDAQ:ME - Post by User

23andMe Holding Co. > i know
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(373)
•••
Post by CTM1967on May 20, 2022 9:37am
306 Views
Post# 34697930

i know

i knowAEM is mining in the area are there any other big players currently mining in Monettas area and how long have they been ....i guess what i am getting at is how much minelife is left in AEM landposition or anyone else for that matter ???


the best potental for Monetta shareholders is if we get bought out by a big guy that already has the nessesary infra structure in place to start mining the deposits Monetta is proving out?!

doeas this make sense?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities